(-0.22%) 5 011.12 points
(0.06%) 37 775 points
(-0.52%) 15 601 points
(-0.15%) $82.61
(-0.74%) $1.744
(-0.12%) $2 395.10
(-0.30%) $28.30
(-0.62%) $948.60
(0.29%) $0.940
(0.64%) $11.06
(0.16%) $0.804
(0.10%) $94.15
@ $11.85
Issued: 14 Feb 2024 @ 13:14
Return: -13.67%
Previous signal: Feb 13 - 12:38
Previous signal:
Return: 1.28 %
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
Today's Volume | 66 841.00 |
Average Volume | 147 282 |
Market Cap | 258.77M |
EPS | $0 ( 2024-03-12 ) |
Next earnings date | ( $-1.160 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.58 |
ATR14 | $0.0260 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
INSIDER POWER |
---|
50.42 |
Last 99 transactions |
Buy: 1 037 036 | Sell: 241 539 |
Volume Correlation
Verastem Inc Correlation
10 Most Positive Correlations | |
---|---|
PXLW | 0.908 |
CVCY | 0.885 |
IMAB | 0.884 |
SRRK | 0.882 |
ADXN | 0.88 |
SHYF | 0.875 |
FOXA | 0.872 |
VIRC | 0.863 |
CRTO | 0.863 |
FLUX | 0.86 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Verastem Inc Correlation - Currency/Commodity
Verastem Inc Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-5 000.00 (0.00 %) |
EPS: | $-1.020 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-5 000.00 (0.00 %) |
EPS: | $-0.750 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-22 000.00 (0.00 %) |
EPS: | $-1.370 |
Financial Reports:
No articles found.
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators